Turkey Pharmaceuticals Market to Grow with a CAGR of 8.96% through 2030
According to
TechSci Research report, “Turkey Pharmaceuticals Market – By Region,
Competition, Forecast & Opportunities, 2030F”, the Turkey
Pharmaceuticals Market stood at USD 9.10 Billion in 2024 and is anticipated to
grow with a CAGR of 7.85% in the forecast period, 2026-2030.
Turkey’s Social
Security Institution (SGK) delivers near-universal healthcare coverage,
underwriting the majority of prescription drug expenses. This extensive public
financing framework significantly broadens patient access to essential
medications across the country. Substantial government funding is directed
towards the development and modernization of healthcare infrastructure,
including the establishment of large-scale city hospitals and upgrading
existing facilities. These enhancements improve healthcare delivery efficiency
and drive increased demand for pharmaceuticals.
Targeted
government incentives—such as tax breaks and grant programs—are actively
supporting the expansion of Turkey’s domestic pharmaceutical manufacturing
sector. With over 70 production facilities nationwide, the country is
prioritizing the local production of both generic drugs and high-value
specialty medicines to reduce import dependency. Turkey’s geostrategic location
at the crossroads of Europe, the Middle East, and North Africa positions it as
a critical regional pharmaceutical export hub. Complemented by export-friendly
policies and trade agreements, Turkish pharmaceutical companies are
increasingly capitalizing on these markets to expand their international
footprint.
The Turkish
Medicines and Medical Devices Agency (TİTCK) has harmonized its regulatory
framework with European Medicines Agency (EMA) standards, enhancing product
quality and market credibility. Reforms including expedited approval processes,
rigorous bioequivalence requirements, and transparent pricing mechanisms are
accelerating product launches and lowering barriers to entry for innovative
therapies. Turkey is investing heavily in biotechnology and pharmaceutical
research, with a strategic focus on developing biosimilars and biologics.
Strengthened collaboration between universities and industry, alongside
initiatives to attract global clinical trials, is fostering a robust innovation
ecosystem aimed at advancing the country’s biopharma capabilities.
Browse over XX
market data Figures spread through XX Pages and an in-depth TOC on "Turkey Pharmaceuticals Market”
The Turkey
Pharmaceuticals Market is segmented into drug type, product type, application,
distribution channel, regional distribution, and company.
Based on its product
type, the Prescription Drugs segment has emerged as the predominant market
leader, Turkey faces a growing prevalence of complex and chronic health
conditions such as cardiovascular diseases, diabetes, cancer, and respiratory
disorders, which require medical supervision and tailored pharmaceutical
interventions. Prescription drugs, by definition, encompass a wide range of
specialized therapies that must be administered under healthcare professional
guidance to ensure efficacy and safety. This clinical necessity places
prescription medications at the forefront of treatment protocols, driving
sustained demand.
Turkey’s
regulatory framework, governed by the Turkish Medicines and Medical Devices
Agency (TİTCK), ensures that prescription drugs meet stringent safety,
efficacy, and quality standards before entering the market. This regulatory
rigor reinforces physician and patient confidence in prescription products. The
country’s universal health coverage system, primarily through the Social
Security Institution (SGK), reimburses a significant portion of prescription
drug costs, enhancing affordability and accessibility. Such reimbursement
policies strongly incentivize the use of prescription medications over
over-the-counter (OTC) alternatives, consolidating their market dominance.
Based on its Distribution Channel, the
Hospital Pharmacy segment has emerged as the predominant market leader, Hospitals in
Turkey serve as primary care centers for diagnosis, treatment, and management
of both acute and chronic diseases. A significant proportion of pharmaceutical
consumption especially high-value, specialized, and inpatient medications occurs
within hospital settings. The hospital pharmacy segment thus commands a
substantial volume of pharmaceutical distribution as it supplies medicines required
for surgeries, oncology treatments, intensive care, and other complex
therapies.
Hospital
pharmacies in Turkey are generally equipped with centralized procurement
systems that negotiate bulk purchasing agreements, often through public tenders
or institutional contracts. This centralized buying power enables hospital
pharmacies to stock a comprehensive range of pharmaceuticals, including
high-cost branded drugs, biologics, and specialty medicines. The scale and
efficiency of hospital pharmacy supply chains ensure reliable availability of
critical medicines, making them the preferred distribution channel for
pharmaceutical companies targeting institutional healthcare providers.
Based on region,
Central Anatolia region has solidified its position as the second largest
pharmaceutical market in Turkey, reflecting a combination of demographic,
economic, and healthcare infrastructure factors that collectively drive robust
pharmaceutical demand. Central Anatolia encompasses major urban centers such as
Ankara, the nation’s capital, which significantly influences regional
healthcare consumption patterns. The region’s sizable and growing population,
characterized by a balanced mix of urban and semi-urban areas, fuels consistent
demand for pharmaceutical products. Ankara’s status as a political and
administrative hub attracts a workforce with higher healthcare awareness and
access, thereby increasing prescription rates and medication utilization.
Central Anatolia
benefits from a relatively advanced healthcare infrastructure compared to other
regions outside Marmara. Ankara and surrounding cities house numerous
state-of-the-art hospitals, specialized medical centers, and research
institutions. These facilities are equipped to provide comprehensive care,
including complex treatments in oncology, cardiology, and neurology, which
require extensive pharmaceutical support. The concentration of tertiary and
quaternary care hospitals enhances pharmaceutical consumption, particularly for
high-value prescription medicines and specialized therapies.
Major companies
operating in Turkey Pharmaceuticals Market are:
- Bilim İlaç Sanayi ve Ticaret A.Ş.
- Pfizer Türkiye
- Novartis Türkiye
- GSK Türkiye
- Menarini Turkey
- Amgen Türkiye
- EastPharma Ltd
- Ferring Türkiye
- Eczacıbaşı Holding A.Ş. (Gensenta
Pharmaceutical Industry and Trade Inc.)
- Takeda Türkiye
- Bristol Myers Squibb Türkiye
- Merck Pharmaceuticals and Chemicals
Trading Inc.
- ITF İLAÇ San. Ve Tic. Ltd. Şti.
- AbbVie Medical Pharmaceuticals Co.
Ltd.
Download Free Sample Report
Customers can
also request for 10% free customization on this report
“The Turkey pharmaceuticals
market stands as a dynamic and rapidly evolving sector, driven by robust
demographic trends, expanding healthcare infrastructure, and progressive
regulatory reforms. With strong government support, increasing chronic disease
prevalence, and growing investment in innovation, the market presents
significant opportunities for both domestic and international pharmaceutical
players. As Turkey continues to modernize its healthcare ecosystem and
strengthen its position as a regional pharmaceutical hub, the industry is well
poised for sustained growth and enhanced contribution to the nation’s public
health and economic development.,” said Mr. Karan Chechi, Research Director of
TechSci Research, a research-based management consulting firm.
“Turkey
Pharmaceuticals Market, By Drug Type (Branded Drugs, Generic Drugs), By Product
Type (Prescription Drugs, Over-The-Counter Drugs), By Application (Oncology,
Metabolic Disorder, Cardiovascular, Anti-infective, Musculoskeletal, Others),
By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, E-Pharmacy), By
Region, Competition, Forecast & Opportunities,
2020-2030F”, has evaluated the future growth potential of Turkey
Pharmaceuticals Market and provides statistics & information on market
size, structure and future market growth. The report intends to provide
cutting-edge market intelligence and help decision makers take sound investment
decisions. Besides, the report also identifies and analyzes the emerging trends
along with essential drivers, challenges, and opportunities in Turkey
Pharmaceuticals Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com